pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,282 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1860Endpoints1444Fierce Biotech764BioSpace754BioPharma Dive546raps249onclive165fda recalls
therapy area
allOncology12879Rare Disease3327Immunology3010Cardiology2846Hematology2294Pulmonology2253Vaccines
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 23h agoPositive readoutPositive↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 1d agoCRLNegative↗ source
← prev
page 2 of 132
next →
118
fda medwatch114
globenewswire health73
fda press61
1852
Psychiatry & CNS1230
Ophthalmology1131
Endocrinology & Metabolism806
Pain790
Nephrology783
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 21h agoRegulatoryNegative↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trial
    German biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • Vertex renews partnership with Genomics in up to $220 million, four-year extension
    Vertex Pharmaceuticals has extended its collaboration with sequencing specialist Genomics, signing a new agreement that can be worth up to $220 million. The extension adds four more years to the e…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competition
    Marrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
    Endpoints · 1d agoDealPositive↗ source
  • Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolio
    Medtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 1d agoNegative↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 1d agoPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 1d agoCRLNegative↗ source
  • EU regulators and industry discuss streamlining combination product oversight at summit
    At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
    raps · 1d agoRegulatoryNeutral↗ source
  • Heidi Overton faces Senate committee vote on FDA commissioner nomination amid uncertainty
    The Trump administration’s nominee for FDA commissioner, Heidi Overton, is scheduled for a vote before the Senate health, education, labor and pensions committee. Lawmakers have not indicated a cl…
    Endpoints · 21h agoRegulatoryNeutral↗ source
  • Cognito Therapeutics readies FDA submission for Alzheimer's light-and-sound headset after trial miss
    Cognito Therapeutics is preparing an FDA submission for its Spectris device, a headset that delivers patterned light and sound therapy aimed at treating Alzheimer's disease. The technology builds o…
    Endpoints · 1d agoRegulatoryNeutral↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 1d agoDealPositive↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 1d agoRegulatoryNeutral↗ source
  • Novo revamps NovoCare DTC platform as Roche’s Gazyva receives renewed approval
    Novo announced a revamp of its direct-to-consumer service, NovoCare, describing it as a reimagined platform for patients. The update includes a refreshed user interface and expanded resources aime…
    Endpoints · 1d agoRegulatoryNeutral↗ source
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 1d agoPositive↗ source
  • Health tech firms eye consumer-driven future at HLTH conference in Las Vegas
    The Endpoints team attended the HLTH conference in Las Vegas despite a ground stop on Friday, gathering insights on health technology trends. Observations suggest the industry is shifting toward c…
    Endpoints · 1d agoNeutral↗ source
  • FDA to call AI "super intelligence" in all official communications
    The FDA announced that it will replace the term "artificial intelligence" with "super intelligence" in its official materials. The change applies to all correspondence, public communications, webs…
    raps · 1d agoRegulatoryNeutral↗ source
  • Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 1d ago↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 1d agoDealPositive↗ source
  • Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns linger
    Helus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
    Endpoints · 1d agoPositive readoutNegative↗ source